Marriage Of Kite’s CAR-T Platform To Amgen Targets Will Expand Pipeline For Both
This article was originally published in The Pink Sheet Daily
Executive Summary
Kite’s initial partnership with another biopharma sees it bringing its CAR-T platform technology to bear on Amgen’s oncology targets. Each company could develop new cancer immunotherapy products out of the collaboration, with earn-outs for the other.
You may also be interested in...
R&D Briefs: Alprolix Approval Bodes Well, T-VEC Stumbles, Curis Back On Track
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.